Table 1.
Baseline characteristics.
| Variable | No. (%) |
|||
|---|---|---|---|---|
| Bamlanivimab (n = 128) |
Bamlanivimab -etesevimab (n = 885) |
Casirivimab -imdevimab (n = 922) |
Entire Cohort (n = 1935) |
|
| Age, mean (SD), years | 57 (17) | 56 (16) | 55 (16) | 56 (16) |
| Female sexa | 69 (54) | 470 (53) | 502 (54) | 1041 (54) |
| Raceb | ||||
| White | 104 (81) | 693 (78) | 701 (76) | 1498 (77) |
| Black | 15 (12) | 148 (17) | 173 (19) | 336 (17) |
| Otherc | 1 (0.8) | 23 (2.6) | 27 (2.9) | 51 (2.6) |
| Unknown | 8 (6.3) | 21 (2.4) | 21 (2.3) | 50 (2.6) |
| Vaccine status | ||||
| Fully vaccinated | 2 (1.6) | 43 (4.9) | 19 (2.1) | 64 (3.3) |
| Partially vaccinated | 26 (20) | 39 (4.4) | 55 (6.0) | 120 (6.2) |
| Unvaccinated | 0 (0) | 27 (3.1) | 30 (3.3) | 57 (2.9) |
| Unknown | 100 (78) | 776 (88) | 818 (89) | 1694 (88) |
| Body mass index, mean (SD)d | 35.6 (9.1) | 34.5 (8.4) | 35.1 (8.4) | 34.8 (8.4) |
| Days from randomization to infusion, mean (SD) |
0.6 (0.9) | 0.4 (0.7) | 0.4 (0.8) | 0.4 (0.8) |
| Days from symptoms to randomization, mean (SD) | 5.0 (2.0) | 5.4 (2.0) | 4.9 (2.0) | 5.0 (2.1) |
| Days from symptoms to infusion, mean (SD) | 6.3 (1.8) | 6.0 (1.9) | 6.2 (2.0) | 6.1 (1.9) |
| Location | ||||
| Infusion center | 103 (81) | 463 (52) | 462 (50) | 1028 (53) |
| Emergency department | 25 (20) | 422 (48) | 460 (50) | 907 (47) |
| Qualifying EUA criteria | ||||
| March 10, 2021–May 23, 2021 | 128 (100) | 753 (85) | 783 (85) | 1664 (86) |
| Age ≥ 65 years | 39 (31) | 223 (30) | 236 (30) | 498 (30) |
| Body mass index ≥ 35d | 33 (47) | 238 (47) | 257 (49) | 528 (48) |
| Chronic kidney disease | 4 (4.0) | 43 (7.7) | 51 (8.8) | 98 (7.9) |
| Diabetes | 24 (24) | 154 (28) | 154 (27) | 332 (27) |
| Immunosuppressive disease or treatmente | 26 (26) | 158 (28) | 155 (27) | 339 (27) |
| Sickle cell disease | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
| Age ≥ 55 years and | ||||
| Cardiovascular disease | 29 (26) | 112 (17) | 117 (17) | 258 (18) |
| Hypertension | 43 (39) | 224 (35) | 223 (33) | 490 (34) |
| Respiratory condition | 29 (26) | 124 (19) | 119 (18) | 272 (19) |
| Age 12–17 years with qualifying criterion | 1 (0.8) | 13 (1.7) | 6 (0.8) | 20 (1.2) |
| May 24, 2021–June 25, 2021f | 0 (0) | 132 (15) | 139 (15) | 271 (14) |
| Age ≥ 65 years | .. | 30 (23) | 37 (27) | 67 (25) |
| Body mass index >25d | .. | 88 (89) | 90 (90) | 178 (89) |
| Chronic kidney disease | .. | 7 (6.6) | 7 (6.5) | 14 (6.5) |
| Diabetes | .. | 29 (27) | 25 (23) | 54 (25) |
| Down syndrome | .. | 0 (0) | 0 (0) | 0 (0) |
| Current or former smoker | .. | 25 (31) | 32 (37) | 57 (34) |
| Current or history of substance abuse | .. | 0 (0) | 2 (2.3) | 2 (1.2) |
| Immunosuppressive disease or treatmente | .. | 29 (27) | 27 (25) | 56 (26) |
| Sickle cell disease | .. | 0 (0) | 0 (0) | 0 (0) |
| Cardiovascular disease | .. | 24 (23) | 14 (13) | 38 (18) |
| Hypertension | .. | 61 (58) | 52 (48) | 113 (53) |
| Respiratory condition | .. | 42 (40) | 40 (37) | 82 (38) |
| Age 12–17 years with qualifying criterion | .. | 1 (0.8) | 2 (1.4) | 3 (1.1) |
Abbreviations: SD, standard deviation; EUA, emergency use authorization.
a
Sex was reported by the patients.
b
Race was reported by the patients.
c
Other includes Chinese, Filipino, Hawaiian, American Indian/Alaskan Native, Asian, Hawaiian/other Pacific Islander, Middle Eastern, Native American, or Pacific Islander.
d
Calculated as weight in kilograms divided by height in meters squared.
e
Immunosuppressive disease or treatment was defined as a history of HIV, cancer, transplant (solid organ, stem cell, bone marrow), chemotherapy treatment, lupus, rheumatoid arthritis, or liver disease.
f
EUA criteria were expanded May 14, 2021, and operationalized at UPMC May 24, 2021.